I-cephalosporin yesizukulwana sesihlanu esibanzi antibiotic, Zevtera (Ceftobiprole medocaril sodium Inj.) yamkelwe ngu FDA1 ukwenzela i impatho izifo ezithathu ezizezi.
- Izifo ze-Staphylococcus aureus zegazi (i-bacteremia) (SAB), kubandakanywa nalabo abane-endocarditis echaphazelekayo ye-right-side;
- Usulelo lwebhaktiriya ebukhali kunye nolwakhiwo lwesikhumba (ABSSSI); kwaye
- inyumoniya yebhaktiriya efunyanwa ngabahlali (CABP).
Oku kulandela iziphumo ezanelisayo zolingo lwezonyango lwesigaba sesi-3.
I-Ceftobiprole medocaril yamkelwe kumazwe amaninzi aseYurophu, kunye naseKhanada kunyango lwenyumoniya efunyenwe esibhedlele (ngaphandle kwenyumoniya efunyenwe yi-ventilator) kunye nenyumoniya efunyanwa luluntu kubantu abadala.2.
E-UK, i-Ceftobiprole medocaril okwangoku ikwisigaba sesi-III solingo lwezonyango3 nangona kunjalo, yamkelwe ukusetyenziswa okuthintelweyo ngaphakathi kwe-NHS Scotland4.
Kwi-EU, kubonakala kwiRejista yeManyano yeemveliso zamayeza ezaliwe ukuze zisetyenziswe ngabantu5.
I-Ceftobiprole medocaril, isizukulwana sesihlanu uluhlu olubanzi I-cephalosporin iyasebenza ngokuchasene neentsholongwane zeGram-positive ezifana ne-methicillin-resistant Staphylococcus aureus kunye ne-penicillin-resistant Streptococcus pneumoniae, kunye ne-Gram-negative bacteria njenge-Pseudomonas aeruginosa. Ifunyaniswe iluncedo ekunyangeni inyumoniya efunyenwe kuluntu kunye nenyumoniya ye-nosocomial, ngaphandle kwenyumoniya ehambelana ne-ventilator.6,7.
***
Iingxelo:
- FDA Ukukhutshwa kweendaba. FDA Ivuma iNtsha Antibiotic kusetyenziso oluThathu olwahlukeneyo. Ithunyelwe nge-03 kuTshazimpuzi 2024. Iyafumaneka e https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses/
- UJame W., uBasgut B., kunye no-Abdi A., 2024. I-Ceftobiprole mono-therapy ngokuchasene nendibaniselwano okanye irejimeni engadibaniyo yomgangatho antibiotics kunyango lwezifo ezinzima: ukuphononongwa okucwangcisiweyo kunye nohlalutyo lwemeta. Uxilongo Microbiology kunye neZifo ezosulelayo. Ifumaneka kwi-intanethi nge-16 Matshi 2024, 116263. DOI: https://doi.org/10.1016/j.diagmicrobio.2024.116263
- I-NIHR. Health Technology Briefing November 2022. I-Ceftobiprole medocaril yokunyanga inyumoniya efunyenwe esibhedlele okanye inyumoniya efunyenwe luluntu efuna ukulaliswa esibhedlele ebantwaneni. Ifumaneka e https://www.io.nihr.ac.uk/wp-content/uploads/2023/04/28893-Ceftobiprole-medocaril-for-pneumonia-V1.0-NOV2022-NONCONF.pdf
- I-Scottish Medicine Consortium. Ceftobiprole medocaril (Zevtera). Ifumaneka e https://www.scottishmedicines.org.uk/medicines-advice/ceftobiprole-medocaril-zevtera-resubmission-94314/
- IKhomishini yaseYurophu. Irejista yeManyano yeemveliso zamayeza ezaliwe ukuze zisetyenziswe ngabantu. Igqityelwe ukuhlaziya nge-21 kaFebruwari 2024. Iyafumaneka e https://ec.europa.eu/health/documents/community-register/html/ho10801.htm
- Lupia T., okqhubekayo 2022. I-Ceftobiprole Perspective: Izibonakaliso zangoku kunye neZinokwenzeka zexesha elizayo. Antibiotics Umqulu 10 Umba 2. DOI: https://doi.org/10.3390/antibiotics10020170
- Méndez1 R., Latorre A., kunye noGonzález-Jiménez P., 2022. Ceftobiprole medocaril. Rev Esp Quimioter. 2022; 35 (Inkxaso 1): 25-27. Ipapashwe kwi-intanethi ngo-2022 Epreli 22. DOI: https://doi.org/10.37201/req/s01.05.2022
***
